Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 trial of KMA.CAR-T for kappa-type multiple myeloma

Trial Profile

Phase 1 trial of KMA.CAR-T for kappa-type multiple myeloma

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KMA CAR T (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors HaemaLogiX

Most Recent Events

  • 27 Jul 2023 New trial record
  • 25 Jul 2023 According to a HaemaLogiX media release, the company has have entered a collaboration agreement with Peter MacCallum Cancer Centre to develop and conduct this trial. Under the agreement, HaemaLogiX brings its patented KappaMab technology to the collaboration with Peter Mac to develop the technology, method of manufacturing and conduct the trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top